Texas, USA-based pharma Neos Therapeutics (Nasdaq: NEOS) has announced the US launch of its Adzenys XR-ODT (amphetamine extended-release orally disintegrating tablet) for attention-deficit/hyperactivity disorder (ADHD).
The treatment is a bioequivalent of Adderall XR (mixed amphetamine salts), which is marketed by Ireland-based pharma company Shire (LSE: SHP).
Adzenys XR-ODT was approved by the US Food and Drug Administration (FDA) in January and is now in distribution channels and available to prescribe to US ADHD patients aged six years and older.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze